Novartis (United Kingdom)

Recent papers from Novartis (United Kingdom)

1. Safety and efficacy of lacnotuzumab, a colony-stimulating factor 1 antibody for the treatment of tenosynovial giant cell tumors: a randomized phase II trialScientific Reports · 2026
2. A Uk Federated Lp(a) Data Network: Interim Findings of Lp(a) Testing Rates in Uk Secondary CareAtherosclerosis · 2026
3. Effects of hyperoxia on pulmonary inflammation and organ injury in a human in vivo model (HIPI): a randomised controlled trialThorax · 2026
4. [177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trialThe Lancet · 2026
5. Physician and Patient Perception of Disease, Symptomatology, and Treatment Administration Preference in Paroxysmal Nocturnal Haemoglobinuria: Results from a Real-World SurveyAdvances in Therapy · 2026
6. Methodological pitfalls in indirect treatment comparisons: insights from a recent systematic review and analysis for C3 glomerulopathyJournal of Comparative Effectiveness Research · 2026
7. Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS studyJournal of Neurology · 2026
8. Adapting UK Clinical Practise in Chronic Myeloid Leukaemia in Chronic Phase to Contemporary Management Recommendations: The ADAPT 2.0 SurveyEuropean Journal Of Haematology · 2026
9. Atrasentan in patients with IgA nephropathy (ALIGN): final 2·5-year results from a randomised, double-blind, placebo-controlled, phase 3 trialThe Lancet · 2026
10. Targeting Fibroblast Activation Protein with [177Lu]Lu-FAP-2286 in Patients with Advanced Solid Tumors in the Phase I LuMIERE TrialClinical Cancer Research · 2026
11. Efficacy and Safety of Treatments for Paroxysmal Nocturnal Hemoglobinuria: A Systematic Literature ReviewJournal of Clinical Medicine · 2026
12. 324eP A real-world overview of HR+/HER2- early breast cancer epidemiology and treatment in England: 2012-2024ESMO Open · 2026
13. 589eP The epidemiology and treatment of HR+/HER2- metastatic breast cancer in England from 2012 to 2024ESMO Open · 2026
14. Impact of Obesity on Individuals in Saudi Arabia: A Real-World Patient and Physician SurveyAdvances in Therapy · 2026
15. Evaluation of Digital Technologies for Home‐Based Assessment in People With Amyotrophic Lateral SclerosisAnnals of Clinical and Translational Neurology · 2026
16. Abstract WE522: Association of Body Roundness Index (BRI) with Left Ventricular Systolic Function: The Framingham Heart StudyCirculation · 2026
17. Abstract TH969: High Left Ventricular Mass on Cardiac Magnetic Resonance Imaging is Associated with Incident Frailty in Community-dwelling AdultsCirculation · 2026
18. Estimating the indirect economic burden of elevated lipoprotein(a): A 5-year simulation of cardiovascular events and associated patient and caregiver costsAmerican Journal of Preventive Cardiology · 2026
19. Indirect treatment comparison of iptacopan versus pegcetacoplan for patients with paroxysmal nocturnal hemoglobinuria and residual anemia despite C5 inhibitor treatmentJournal of Comparative Effectiveness Research · 2026
20. Advancing Pharmacometrics in Africa: Insights and Perspectives From the 2025 Pharmacometrics Africa Conference.2026